A Randomized, Double Blind, Placebo Controlled Phase III Study of Fruquitinib in Combination With Paclitaxel in Second Line Gastric Cancer

Trial Profile

A Randomized, Double Blind, Placebo Controlled Phase III Study of Fruquitinib in Combination With Paclitaxel in Second Line Gastric Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Fruquintinib (Primary) ; Paclitaxel
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FRUTIGA
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 31 Jul 2017 According to a Chi-Med media release, Phase III trial will be initiated in late 2017 or early 2018 in China.
    • 18 Jul 2017 Status changed from planning to not yet recruiting.
    • 08 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top